A reorganization of manufacturing sites is currently underway in the generic drug industry. With the generic drug share approaching 80% on a volume basis and NHI prices in decline, companies are looking for ways to grow and survive.In July, Nichi-Iko…
ORGANIZATION
Pharmacist Group Says Drug Price Survey This Year “Utterly Unacceptable”
The Japan Pharmaceutical Association (JPA) expressed strong discomfort on July 17 against the government’s plan confirmed in its annual policy blueprint to conduct a drug price survey this year for “off-year” re-pricing scheduled for FY2021 despite the COVID-19 crisis. The…
To read the full story
Related Article
ORGANIZATION
- JPMA Girding for Culmination in Off-Year Re-Pricing, Tax Debates Late November-Early December: Exec
November 20, 2020
- EFPIA Japan Chief Frets Declining Priority for Japan Market since 2018 Pricing Overhaul
November 19, 2020
- Active Hep C Treatment Estimated to Save 1.3 Trillion Yen in Healthcare Costs in 20 Years: INES
November 18, 2020
- JPMA Sorts Out Challenges for Remote Clinical Trial to Promote Its Introduction in Japan
November 9, 2020
- Raise Copay Rates to 20% for Seniors Over 75 ASAP: 5 Insurers
November 5, 2020
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As I skied the slopes of Hakuba in January, I never would have imagined the world would be in a complete lockdown just a few months later. There’s no question this has been an incredibly challenging year, but there’s good…